# A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma

> **NCT05840289** · — · UNKNOWN · sponsor: **University Hospital, Geneva** · enrollment: 94 (actual)

## Conditions studied

- Aggressive B-Cell Non-Hodgkin Lymphoma

## Interventions

- **OTHER:** fractionated first dose rituximab

## Key facts

- **NCT ID:** NCT05840289
- **Lead sponsor:** University Hospital, Geneva
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-24
- **Primary completion:** 2023-05-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05840289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05840289, "A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05840289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*